Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2013 · 10-Q
Revenue$16.01M$16.01M+200.2% vs Q3 2012 Net Income-$19.29M-$19.29MN/M vs Q3 2012 EPS Diluted-$0.17-$0.17N/M vs Q3 2012 Gross Profit$9,342,000+1,811.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$12,414,000N/M Free Cash Flowderived-$12,739,000N/M Margins · derivedGross margin58.3%+49.2 pt vs Q3 2012
Operating margin-115.5%+260.0 pt vs Q3 2012
Net margin-120.5%+254.6 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 8, 2013 · 39 d after period end